Showing 4151-4160 of 10627 results for "".
Impacts on Access to Eye Care: Key Socioeconomic Factors
https://reachmd.com/programs/clinicians-roundtable/impacts-on-access-to-eye-care-key-socioeconomic-factors/14631/Have recent findings helped clinicians better identify socioeconomic factors among patients with glaucoma? Find out.MAPLE-HCM Results: Favorable Safety and Efficacy for Aficamten in oHCM
https://reachmd.com/clinical-practice/cardiology/maple-hcm-results-favorable-safety-and-efficacy-for-aficamten-in-ohcm/37255/Dr. Garcia shares the latest data from the MAPLE-HCM trial of aficamten compared with metoprolol in patients with oHCM. Tune in to hear the significance.The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
https://reachmd.com/clinical-practice/nephrology/the-impact-of-finerenone-plus-empagliflozin-on-hyperkalemia-in-the-confidence-trial/39960/Join Dr. Agarwal from the Kidney Meeting 2025 in Houston as he interprets key findings regarding hyperkalemia from the CONFIDENCE trial.Diving into New Directions of Radiopharmaceuticals
https://reachmd.com/programs/project-oncology/diving-into-new-directions-of-radiopharmaceuticals/24059/Tune in to hear about radiopharmaceuticals.Exploring the Latest in MS Cognitive Rehabilitation Strategies
https://reachmd.com/programs/neurofrontiers/exploring-the-latest-in-ms-cognitive-rehabilitation-strategies/18041/At what point in the MS process should we be providing cognitive rehabilitation to the patient? Tune in.Salivary Toxicity from PSMA-Targeted Radiopharmaceuticals in mCRPC
https://reachmd.com/programs/project-oncology/salivary-toxicity-from-psma-targeted-radiopharmaceuticals-in-mcrpc/17947/What should we know about salivary toxicity? Tune in.When Alopecia Areata Signals More than Hair Loss
https://reachmd.com/programs/dermconsult/alopecia-areata-more-than-hair-loss/49023/Challenges of Implementing Evidence-Based Guidance for IgA Nephropathy
https://reachmd.com/programs/kdigo-conversations-nephrology/challenges-of-implementing-evidence-based-guidance-for-iga-nephropathy/37118/In this episode of KDIGO Conversations in Nephrology, host Dr. Dana Rizk welcomes Dr. Suneel Udani to discuss the challenges and opportunities of adopting the updated KDIGO guidelines for IgA nephropathy (IgAN). Their conversation highlights a shift in therapeutic goals and a new paradigm of simultaCLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
https://reachmd.com/programs/project-oncology/cll17-trial-fixed-continuous-therapy-frontline-cll/39975/At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous BTK inhibition with fixed-duration venetoclax-based therapy in previously untrIdentifying Mpox Hospitalization Risks in Patients with HIV During the 2022 Outbreak
https://reachmd.com/programs/clinicians-roundtable/identifying-mpox-hospitalization-risks-in-patients-with-hiv-during-the-2022-outbreak/32853/During the 2022 mpox outbreak, New York City emerged as the epicenter, with disproportionate impacts on gay and bisexual men. A new study presented at IDWeek 2025 examines how HIV-related factors, such as CD4 count, ART status, and syphilis co-infection, shaped mpox severity and hospitalization risk